 | • レポートコード：GIR-2104Z06887 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、肝性脳症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。肝性脳症治療薬の種類別市場規模（キット、試薬、機器）、用途別市場規模（急性肝不全、非肝疾患門脈全身バイパス、肝硬変）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・肝性脳症治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：ASKA Pharmaceutical、COSMO Pharmaceuticals、Fresenius Kabi、Mallinckrodt Pharmaceuticals、Lupin、Salix Pharmaceuticals、Teva Pharmaceutical、Bausch Health ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：キット、試薬、機器 ・用途別分析2016年-2026年：急性肝不全、非肝疾患門脈全身バイパス、肝硬変 ・肝性脳症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・肝性脳症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・肝性脳症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・肝性脳症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・肝性脳症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Hepatic Encephalopathy Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Hepatic Encephalopathy Therapeutics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Hepatic Encephalopathy Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Hepatic Encephalopathy Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Kits
Reagents
Instruments
Market segment by Application, can be divided into
Acute Liver Failure
Portal Systemic Bypass without Liver Disease
Liver Cirrhosis
Market segment by players, this report covers
ASKA Pharmaceutical
COSMO Pharmaceuticals
Fresenius Kabi
Mallinckrodt Pharmaceuticals
Lupin
Salix Pharmaceuticals
Teva Pharmaceutical
Bausch Health
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Hepatic Encephalopathy Therapeutics
1.2 Classification of Hepatic Encephalopathy Therapeutics by Type
1.2.1 Overview: Global Hepatic Encephalopathy Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Type in 2020
1.2.3 Kits
1.2.4 Reagents
1.2.5 Instruments
1.3 Global Hepatic Encephalopathy Therapeutics Market by Application
1.3.1 Overview: Global Hepatic Encephalopathy Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Acute Liver Failure
1.3.3 Portal Systemic Bypass without Liver Disease
1.3.4 Liver Cirrhosis
1.4 Global Hepatic Encephalopathy Therapeutics Market Size & Forecast
1.5 Global Hepatic Encephalopathy Therapeutics Market Size and Forecast by Region
1.5.1 Global Hepatic Encephalopathy Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Hepatic Encephalopathy Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Hepatic Encephalopathy Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Hepatic Encephalopathy Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Hepatic Encephalopathy Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Hepatic Encephalopathy Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Hepatic Encephalopathy Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Hepatic Encephalopathy Therapeutics Market Drivers
1.6.2 Hepatic Encephalopathy Therapeutics Market Restraints
1.6.3 Hepatic Encephalopathy Therapeutics Trends Analysis
2 Company Profiles
2.1 ASKA Pharmaceutical
2.1.1 ASKA Pharmaceutical Details
2.1.2 ASKA Pharmaceutical Major Business
2.1.3 ASKA Pharmaceutical Hepatic Encephalopathy Therapeutics Product and Solutions
2.1.4 ASKA Pharmaceutical Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 ASKA Pharmaceutical Recent Developments and Future Plans
2.2 COSMO Pharmaceuticals
2.2.1 COSMO Pharmaceuticals Details
2.2.2 COSMO Pharmaceuticals Major Business
2.2.3 COSMO Pharmaceuticals Hepatic Encephalopathy Therapeutics Product and Solutions
2.2.4 COSMO Pharmaceuticals Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 COSMO Pharmaceuticals Recent Developments and Future Plans
2.3 Fresenius Kabi
2.3.1 Fresenius Kabi Details
2.3.2 Fresenius Kabi Major Business
2.3.3 Fresenius Kabi Hepatic Encephalopathy Therapeutics Product and Solutions
2.3.4 Fresenius Kabi Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Fresenius Kabi Recent Developments and Future Plans
2.4 Mallinckrodt Pharmaceuticals
2.4.1 Mallinckrodt Pharmaceuticals Details
2.4.2 Mallinckrodt Pharmaceuticals Major Business
2.4.3 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Therapeutics Product and Solutions
2.4.4 Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Mallinckrodt Pharmaceuticals Recent Developments and Future Plans
2.5 Lupin
2.5.1 Lupin Details
2.5.2 Lupin Major Business
2.5.3 Lupin Hepatic Encephalopathy Therapeutics Product and Solutions
2.5.4 Lupin Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Lupin Recent Developments and Future Plans
2.6 Salix Pharmaceuticals
2.6.1 Salix Pharmaceuticals Details
2.6.2 Salix Pharmaceuticals Major Business
2.6.3 Salix Pharmaceuticals Hepatic Encephalopathy Therapeutics Product and Solutions
2.6.4 Salix Pharmaceuticals Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Salix Pharmaceuticals Recent Developments and Future Plans
2.7 Teva Pharmaceutical
2.7.1 Teva Pharmaceutical Details
2.7.2 Teva Pharmaceutical Major Business
2.7.3 Teva Pharmaceutical Hepatic Encephalopathy Therapeutics Product and Solutions
2.7.4 Teva Pharmaceutical Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Teva Pharmaceutical Recent Developments and Future Plans
2.8 Bausch Health
2.8.1 Bausch Health Details
2.8.2 Bausch Health Major Business
2.8.3 Bausch Health Hepatic Encephalopathy Therapeutics Product and Solutions
2.8.4 Bausch Health Hepatic Encephalopathy Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Bausch Health Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Hepatic Encephalopathy Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Hepatic Encephalopathy Therapeutics Players Market Share
3.2.2 Top 10 Hepatic Encephalopathy Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Hepatic Encephalopathy Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Hepatic Encephalopathy Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Hepatic Encephalopathy Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Hepatic Encephalopathy Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2026)
6.2 North America Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2026)
6.3 North America Hepatic Encephalopathy Therapeutics Market Size by Country
6.3.1 North America Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2026)
7.2 Europe Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2026)
7.3 Europe Hepatic Encephalopathy Therapeutics Market Size by Country
7.3.1 Europe Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Hepatic Encephalopathy Therapeutics Market Size by Region
8.3.1 Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Region (2016-2026)
8.3.2 China Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2026)
9.2 South America Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2026)
9.3 South America Hepatic Encephalopathy Therapeutics Market Size by Country
9.3.1 South America Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Hepatic Encephalopathy Therapeutics Market Size by Country
10.3.1 Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Hepatic Encephalopathy Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Hepatic Encephalopathy Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Hepatic Encephalopathy Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Hepatic Encephalopathy Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Hepatic Encephalopathy Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. ASKA Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 7. ASKA Pharmaceutical Major Business
Table 8. ASKA Pharmaceutical Hepatic Encephalopathy Therapeutics Product and Solutions
Table 9. ASKA Pharmaceutical Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. COSMO Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. COSMO Pharmaceuticals Major Business
Table 12. COSMO Pharmaceuticals Hepatic Encephalopathy Therapeutics Product and Solutions
Table 13. COSMO Pharmaceuticals Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Fresenius Kabi Corporate Information, Head Office, and Major Competitors
Table 15. Fresenius Kabi Major Business
Table 16. Fresenius Kabi Hepatic Encephalopathy Therapeutics Product and Solutions
Table 17. Fresenius Kabi Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Mallinckrodt Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 19. Mallinckrodt Pharmaceuticals Major Business
Table 20. Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Therapeutics Product and Solutions
Table 21. Mallinckrodt Pharmaceuticals Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Lupin Corporate Information, Head Office, and Major Competitors
Table 23. Lupin Major Business
Table 24. Lupin Hepatic Encephalopathy Therapeutics Product and Solutions
Table 25. Lupin Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Salix Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Salix Pharmaceuticals Major Business
Table 28. Salix Pharmaceuticals Hepatic Encephalopathy Therapeutics Product and Solutions
Table 29. Salix Pharmaceuticals Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Teva Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 31. Teva Pharmaceutical Major Business
Table 32. Teva Pharmaceutical Hepatic Encephalopathy Therapeutics Product and Solutions
Table 33. Teva Pharmaceutical Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 35. Bausch Health Major Business
Table 36. Bausch Health Hepatic Encephalopathy Therapeutics Product and Solutions
Table 37. Bausch Health Hepatic Encephalopathy Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Global Hepatic Encephalopathy Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 39. Global Hepatic Encephalopathy Therapeutics Revenue Share by Players (2019-2021)
Table 40. Breakdown of Hepatic Encephalopathy Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 41. Hepatic Encephalopathy Therapeutics Players Head Office, Products and Services Provided
Table 42. Hepatic Encephalopathy Therapeutics Mergers & Acquisitions in the Past Five Years
Table 43. Hepatic Encephalopathy Therapeutics New Entrants and Expansion Plans
Table 44. Global Hepatic Encephalopathy Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 45. Global Hepatic Encephalopathy Therapeutics Revenue Share by Type (2016-2021)
Table 46. Global Hepatic Encephalopathy Therapeutics Revenue Forecast by Type (2021-2026)
Table 47. Global Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2021)
Table 48. Global Hepatic Encephalopathy Therapeutics Revenue Forecast by Application (2021-2026)
Table 49. North America Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 50. North America Hepatic Encephalopathy Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 51. North America Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 52. North America Hepatic Encephalopathy Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 53. North America Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 54. North America Hepatic Encephalopathy Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 55. Europe Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 56. Europe Hepatic Encephalopathy Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 57. Europe Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 58. Europe Hepatic Encephalopathy Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 59. Europe Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 60. Europe Hepatic Encephalopathy Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 61. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 62. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 63. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 64. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 65. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 66. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 67. South America Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 68. South America Hepatic Encephalopathy Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 69. South America Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 70. South America Hepatic Encephalopathy Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 71. South America Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 72. South America Hepatic Encephalopathy Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 73. Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 74. Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 75. Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 76. Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 77. Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 78. Middle East & Africa Hepatic Encephalopathy Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Hepatic Encephalopathy Therapeutics Picture
Figure 2. Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Type in 2020
Figure 3. Kits
Figure 4. Reagents
Figure 5. Instruments
Figure 6. Hepatic Encephalopathy Therapeutics Revenue Market Share by Application in 2020
Figure 7. Acute Liver Failure Picture
Figure 8. Portal Systemic Bypass without Liver Disease Picture
Figure 9. Liver Cirrhosis Picture
Figure 10. Global Hepatic Encephalopathy Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Hepatic Encephalopathy Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Hepatic Encephalopathy Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Hepatic Encephalopathy Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Hepatic Encephalopathy Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Hepatic Encephalopathy Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Hepatic Encephalopathy Therapeutics Market Drivers
Figure 19. Hepatic Encephalopathy Therapeutics Market Restraints
Figure 20. Hepatic Encephalopathy Therapeutics Market Trends
Figure 21. ASKA Pharmaceutical Recent Developments and Future Plans
Figure 22. COSMO Pharmaceuticals Recent Developments and Future Plans
Figure 23. Fresenius Kabi Recent Developments and Future Plans
Figure 24. Mallinckrodt Pharmaceuticals Recent Developments and Future Plans
Figure 25. Lupin Recent Developments and Future Plans
Figure 26. Salix Pharmaceuticals Recent Developments and Future Plans
Figure 27. Teva Pharmaceutical Recent Developments and Future Plans
Figure 28. Bausch Health Recent Developments and Future Plans
Figure 30. Global Hepatic Encephalopathy Therapeutics Revenue Share by Players in 2020
Figure 31. Hepatic Encephalopathy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 32. Global Top 3 Players Hepatic Encephalopathy Therapeutics Revenue Market Share in 2020
Figure 33. Global Top 10 Players Hepatic Encephalopathy Therapeutics Revenue Market Share in 2020
Figure 34. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 35. Global Hepatic Encephalopathy Therapeutics Revenue Share by Type in 2020
Figure 36. Global Hepatic Encephalopathy Therapeutics Market Share Forecast by Type (2021-2026)
Figure 37. Global Hepatic Encephalopathy Therapeutics Revenue Share by Application in 2020
Figure 38. Global Hepatic Encephalopathy Therapeutics Market Share Forecast by Application (2021-2026)
Figure 39. North America Hepatic Encephalopathy Therapeutics Sales Market Share by Type (2016-2026)
Figure 40. North America Hepatic Encephalopathy Therapeutics Sales Market Share by Application (2016-2026)
Figure 41. North America Hepatic Encephalopathy Therapeutics Revenue Market Share by Country (2016-2026)
Figure 42. United States Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Hepatic Encephalopathy Therapeutics Sales Market Share by Type (2016-2026)
Figure 46. Europe Hepatic Encephalopathy Therapeutics Sales Market Share by Application (2016-2026)
Figure 47. Europe Hepatic Encephalopathy Therapeutics Revenue Market Share by Country (2016-2026)
Figure 48. Germany Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. France Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. United Kingdom Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Russia Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Italy Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Asia-Pacific Hepatic Encephalopathy Therapeutics Sales Market Share by Type (2016-2026)
Figure 54. Asia-Pacific Hepatic Encephalopathy Therapeutics Sales Market Share by Application (2016-2026)
Figure 55. Asia-Pacific Hepatic Encephalopathy Therapeutics Revenue Market Share by Region (2016-2026)
Figure 56. China Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Japan Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. South Korea Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. India Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Southeast Asia Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Australia Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South America Hepatic Encephalopathy Therapeutics Sales Market Share by Type (2016-2026)
Figure 63. South America Hepatic Encephalopathy Therapeutics Sales Market Share by Application (2016-2026)
Figure 64. South America Hepatic Encephalopathy Therapeutics Revenue Market Share by Country (2016-2026)
Figure 65. Brazil Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Argentina Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Middle East and Africa Hepatic Encephalopathy Therapeutics Sales Market Share by Type (2016-2026)
Figure 68. Middle East and Africa Hepatic Encephalopathy Therapeutics Sales Market Share by Application (2016-2026)
Figure 69. Middle East and Africa Hepatic Encephalopathy Therapeutics Revenue Market Share by Country (2016-2026)
Figure 70. Turkey Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Saudi Arabia Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. UAE Hepatic Encephalopathy Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Methodology
Figure 74. Research Process and Data Source
世界の肝性脳症（HE）治療市場規模・現状・予測（2021年-2027年） HE is a potentially fatal brain disorder that is caused by liver damage, which results in the failure to remove toxins from the blood. The availability of patient-focused programs to assist disease management is one of the primary growth drivers for the global hepatic encephalopathy (HE) therapeutic…- 世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年） Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma. Overt hepatic encephalopathy develo…
- 世界の顕性肝性脳症市場規模・現状・予測（2021年-2027年） Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma. Overt hepatic encephalopathy develo…
- 世界の代謝障害治療市場規模・現状・予測（2021年-2027年） Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes. Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the f…
- 世界の代謝障害治療市場規模・現状・予測（2021年-2027年） Metabolic Disorders Therapeutics is a drug used to treat the symptoms of metabolic disorders caused by a variety of causes. Due to the increasing pressure of modern life and the spread of unhealthy lifestyles, the global metabolic disorder treatment market will continue to grow strongly during the f…